German pharmaceutical company Boehringer Ingelheim GmbH on Tuesday said it expects sales to rise by a high-single-digit percentage this year, as its 2011 after-tax profit surged, boosted by sales of blockbuster drugs such as Pradaxa and Spiriva. The company’s sales will accelerate over the course of this year with a positive effect on profitability, Chief Executive Andreas Barner said. Sales are also expected to be higher in 2013, he said. Boehringer said its 2011 after-tax profit jumped 66% to EUR1.48 billion, while sales grew 5% to EUR13.2 billion.
